May 29, 2019
Ansun Biopharma opens door for patients to test its medication for certain parainfluenza virus infection
Ansun Biopharma has welcomed the first patient to its Phase 3 clinical trial to test DAS181 a recombinant sialidase protein that can cleave sialic acid, the virus receptors located on the surface of epithelial cells lining the human respiratory track.